Učitavanje...
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...
Spremljeno u:
| Izdano u: | Drug Healthc Patient Saf |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4687626/ https://ncbi.nlm.nih.gov/pubmed/26719727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S97113 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|